4:30 PM - 4:45 PM (JST), Tuesday, March 5, 2019 ・ 2nd Floor
Shaperon is a biotech company navigating in the universe of immunology and inflammation. Its flagship small molecule, HY209, is a TGR5 receptor agonist (first of its kind to treat inflammatory diseases) with pharmacological mode of action best suited for complex inflammatory conditions. Our R&D pipeline includes the treatment for atopic dermatitis (phase I completed), sepsis (phase I IND submission), ulcerative colitis/alzheimer's disease (pre-clinical).

By blocking NF-kB signaling, HY209 inhibits TSLP gene expression. What makes HY209 unique is its dual MoA. In addition to blocking NF-kB signaling, HY209 increases the number of regulatory T cells s, thus restoring Th1/Th2 balance. In DNCB animal model, HY209-treated group demonstrated excellent outcome in lowering pro-inflammatory proteins such as lgE, IL-4, IL-13, IL-33, and TSLP, normalizing epidermal/dermal thickness, and lowering number of infiltrating cells, thus resulting in better efficacy than existing treatment options.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
TGR 5 agonist, HY209
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):